The ‘unmet need’
An estimated 9.6 million people died from cancer in 2018, making it the second-leading cause of death worldwide. Although advances in cancer research over the past decades have shed light on how normal cells undergo oncogenic transformation and have spurred the development of targeted therapeutics, there is clearly still an unmet need to improve cancer detection and bring new treatment options to patients.
To address this, PLOS ONE and PLOS Computational Biology have solicited contributions to a Collection on Targeted Anticancer Therapies and Precision Medicine in Cancer. Articles in this Collection will be specially selected by a panel of Guest Editors and will include research on translational and clinically relevant areas, including identification and classification of driver genes and mutations, target and drug discovery, mechanisms of drug resistance, and early detection and screening. The broad reach of the journals and high interest in this topic could mean that this Collection will be read, discussed, cited and appreciated by a wide audience of researchers, clinicians, policymakers and patients.
Dr. Sunil Krishnan, one of the guest editors for the Collection, said:
“A recent renaissance in precision medicine has shifted from small molecules and antibodies to novel discovery tools for identifying druggable targets/driver genes, defining their functional significance, developing designer drugs for even undruggable targets, and overcoming therapeutic resistance. Much of this is at the interface to disparate disciplines like informatics, chemistry, pharmaceutics, biology, and physics. This PLOS Collection provides a venue for coalescing and converging research in these arenas.”
Be considered for the Collection
Manuscript submission deadline: 21 June 2019.
The Collection will begin publishing in November 2019.
- More information: collections.plos.org/s/targeted-anticancer-therapies
- Email contact: email@example.com